Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 28, 2015 1:10 AM ET


Company Overview of OncoMed Pharmaceuticals, Inc.

Company Overview

OncoMed Pharmaceuticals, Inc., a clinical development-stage biotechnology company, discovers and develops protein therapeutics targeting cancer stem cells (CSCs). Its product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, as well as impact bulk tumor cells. The company’s product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), a humanized monoclonal antibody that is in two Phase II clinical trials and one Phase Ib/II clinical trial for the treatment of patients with non-small-cell lung cancer and pancreatic cancer; Anti-DLL4/Anti-vascular endothelial growth factor (VEGF) Bispecific, which has c...

800 Chesapeake Drive

Redwood City, CA 94063

United States

Founded in 2004

108 Employees





Key Executives for OncoMed Pharmaceuticals, Inc.

Chairman, Chief Executive Officer and President
Age: 55
Total Annual Compensation: $469.5K
Vice President and General Counsel
Age: 45
Total Annual Compensation: $383.8K
Chief Medical Officer and Senior Vice President
Age: 50
Total Annual Compensation: $377.2K
Chief Scientific Officer and Executive Vice President
Age: 63
Total Annual Compensation: $364.7K
Compensation as of Fiscal Year 2014.

OncoMed Pharmaceuticals, Inc. Key Developments

OncoMed Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

OncoMed Pharmaceuticals, Inc. announced unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported collaboration revenues of $4.7 million, as compared to $6.0 million in the second quarter of 2014.  The decrease in revenue over the same period in 2014 was primarily due to a change in the amortization of upfront payment fees under partnership with Bayer. Net loss was $21.6 million or $0.72 per share, compared to $15.6 million or $0.53 per share for the same three-month period of 2014. The change in net loss for second quarter of 2015 was primarily due to an increase in operational expenses, especially research and development costs. Loss from operations was $21,635,000 against $15,592,000 for the same period a year ago. Loss before provision for income taxes was $21,608,000 against $15,586,000 for the same period a year ago. For the six months, the company reported collaboration revenue of $14,374,000 against $12,030,000 for the same period a year ago. Loss from operations was $36,175,000 against $29,499,000 for the same period a year ago. Loss before provision for income taxes was $36,126,000 against $29,455,000 for the same period a year ago. Net loss was $36,149,000 compared to $29,468,000 a year ago. Basic and diluted net loss per common share was $1.21 compared to $1.00 a year ago.

OncoMed Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 10, 2015

OncoMed Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 10, 2015

OncoMed Pharmaceuticals, Inc. to Report Q2, 2015 Results on Aug 10, 2015

OncoMed Pharmaceuticals, Inc. announced that they will report Q2, 2015 results After-Market on Aug 10, 2015

Similar Private Companies By Industry

Company Name Region
Cardinal Health 420, LLC United States
GE Healthcare Inc. United States
Clearside BioMedical, Inc. United States
Syndax Pharmaceuticals, Inc. United States
MJ GeneWorks, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OncoMed Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at